• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying

    7/22/24 8:58:39 AM ET
    $BHVN
    $CSPI
    $PTWO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $BHVN alert in real time by email

    Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform.

    Biohaven

    • The Trade: Biohaven Ltd. (NYSE:BHVN) Director John W Childs acquired a total of 28,400 shares at an average price of $35.67. To acquire these shares, it cost around $1.01 million.
    • What's Happening: On July 1, Benitec Biopharma announced appointment of Kishen Mehta to its Board of Directors.
    • What Biohaven Does: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.

    CSP

    • The Trade: CSP Inc. (NASDAQ:CSPI) 10% owner Joseph R Nerges acquired a total of 2,726 shares at </em></a> an average price of $14.39. To acquire these shares, it cost around $39,235.
    • What's Happening: On May 8, CSP reported an increase in EPS for the second quarter.
    • What CSP Does: CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems.

    Pono Capital Two

    • The Trade: Pono Capital Two, Inc. (NASDAQ:PTWO) 10% owner Kazumasa Tomita bought a total of 5,406 shares at an average price of $13.00. To acquire these shares, it cost around $70,278.
    • What's Happening: On Aug. 4, Pono Capital Two announced pricing of $100,000,000 initial public offering.
    • What Pono Capital Two Does: Pono Capital Two Inc is a shell company.

    Read More:

    • Top 3 Industrials Stocks That May Rocket Higher In Q3
    Get the next $BHVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHVN
    $CSPI
    $PTWO

    CompanyDatePrice TargetRatingAnalyst
    Biohaven Ltd.
    $BHVN
    2/6/2026$23.00Buy
    Goldman
    Biohaven Ltd.
    $BHVN
    1/21/2026$22.00Sector Perform → Outperform
    RBC Capital Mkts
    Biohaven Ltd.
    $BHVN
    12/3/2025$11.00Buy → Neutral
    H.C. Wainwright
    Biohaven Ltd.
    $BHVN
    11/26/2025$11.00Buy → Neutral
    UBS
    Biohaven Ltd.
    $BHVN
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    Biohaven Ltd.
    $BHVN
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    Biohaven Ltd.
    $BHVN
    9/17/2025$28.00Buy
    Citigroup
    Biohaven Ltd.
    $BHVN
    9/3/2025$75.00Strong Buy
    Raymond James
    More analyst ratings

    $BHVN
    $CSPI
    $PTWO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

    Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity:Inflammation and Immunology:Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of Ig

    3/2/26 4:05:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

    Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date:IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing of

    1/12/26 11:15:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

    NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 12, 2026, at 8:15 a.m. PST (11:15 a.m. EST). About Biohaven Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience and oncology. Biohaven is ad

    1/7/26 7:00:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $CSPI
    $PTWO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Nerges Joseph R bought $26,366 worth of shares (3,000 units at $8.79), increasing direct ownership by 0.21% to 1,409,075 units (SEC Form 4)

    4 - CSP INC /MA/ (0000356037) (Issuer)

    2/26/26 3:27:13 PM ET
    $CSPI
    EDP Services
    Technology

    Large owner Nerges Joseph R bought $101,525 worth of shares (11,012 units at $9.22), increasing direct ownership by 0.79% to 1,406,075 units (SEC Form 4)

    4 - CSP INC /MA/ (0000356037) (Issuer)

    2/19/26 1:48:39 PM ET
    $CSPI
    EDP Services
    Technology

    $BHVN
    $CSPI
    $PTWO
    SEC Filings

    View All

    Biohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Biohaven Ltd. (0001935979) (Filer)

    3/2/26 4:32:34 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Biohaven Ltd.

    S-8 - Biohaven Ltd. (0001935979) (Filer)

    3/2/26 4:30:08 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Biohaven Ltd.

    10-K - Biohaven Ltd. (0001935979) (Filer)

    3/2/26 4:09:33 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $CSPI
    $PTWO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Biohaven with a new price target

    Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00

    2/6/26 8:10:57 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Biohaven from Sector Perform to Outperform and set a new price target of $22.00

    1/21/26 8:29:40 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Biohaven from Buy to Neutral and set a new price target of $11.00

    12/3/25 7:48:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $CSPI
    $PTWO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Buten Matthew

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/3/26 6:09:03 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Clinical Operations Gentile Kimberly

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/3/26 6:08:17 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $CSPI
    $PTWO
    Financials

    Live finance-specific insights

    View All

    CSPi Reports Fiscal Fourth Quarter and Full Year 2024 Results; Recurring Sales Continue to Rise as Percentage of Total Revenue; AZT PROTECT Market Momentum Builds; Cash Position of More Than $30 Million as of September 30, 2024

    Board Declares $0.03 per Share Quarterly Dividend LOWELL, MA / ACCESSWIRE / December 20, 2024 / CSP Inc. (NASDAQ:CSPI), an award-winning provider of security and packet capture products, managed IT and professional services and technology solutions, today announced results for the fiscal fourth quarter and year ended September 30, 2024. The Company also announced that the Board of Directors declared a quarterly dividend of $0.03 per share payable January 15, 2025, to shareholders of record at the close of business on December 27, 2024.Recent Achievements and Operating HighlightsCloud-based business remains strong with over 10 new customers signed in the fourth quarter.Recurring revenue incre

    12/20/24 8:00:00 AM ET
    $CSPI
    EDP Services
    Technology

    CSPi to Announce Fiscal Fourth Quarter and Full Year Results on December 20, 2024

    LOWELL, MA / ACCESSWIRE / December 18, 2024 / CSPi (NASDAQ:CSPI), an award-winning provider of security and packet capture products, managed IT and professional services and technology solutions, announced that it will issue its fiscal 2024 fourth quarter and full year financial results before the open of the market on Friday December 20, 2024.CSPi President and Chief Executive Officer Victor Dellovo and Chief Financial Officer Gary W. Levine will host a conference call at 10:00 a.m. ET that day to review the financial results and provide a business update. To listen to a live webcast of the call, the event link is https://www.webcaster4.com/Webcast/Page/2912/51805 Individuals also may liste

    12/18/24 11:00:00 AM ET
    $CSPI
    EDP Services
    Technology

    Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

    Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

    9/23/24 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $CSPI
    $PTWO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/14/24 3:06:46 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/12/24 1:20:24 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/4/24 11:16:33 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $CSPI
    $PTWO
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    7/1/24 7:00:00 AM ET
    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

    Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

    5/12/23 4:30:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care